Patent Daily RSS
December 2019 M T W T F S S « Nov 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Twitter Guna
- Happy #gobackmodi day 10 months ago
- RT @nikhilkarani1: Aurobindo acquires oral solid & derm Biz of Sandoz - Acqd Biz has sales worth $1.2bn & Aurobindo wud pay $900mn in cash… 1 year ago
- RT @ainvvy: 0. On Independence day, I look briefly at how some of the current states came into being. Some of them I had not even heard be… 1 year ago
- RT @digvijaya_28: Political turmoil in TN and Governor playing truant. Is he fulfilling his duties ? No. He is doing politics under directi… 2 years ago
- RT @VikasDandekarET: #Cipla bets on speciality #pharma business in US; aims for commercial launches by 2020 economictimes.indiatimes.com/industry/healt… 3 years ago
- RT @scarthik: @itisprashanth வாழ்வில் நமதுதேவை குறித்த தெளிவான தேர்வும், அதைநோக்கிய நேர்மையான தேடலும்இருந்துவிட்டால், வெற்றி கூடிவரும். அமை… 3 years ago
Tag Archives: Cipla
Deferacirox-composition-pregrant oppoisition-india
A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1). This application is refused under lack of inventive … Continue reading
CL application for Raltegravir in India
Toady SpicyIP reported filing of compulsory license for Raltegravir by Cipla [SpicyIP] Some additional info: Raltegravir seems to be protected by 212400 (868/CHENP/2004) assigned to Istituto Di Ricerche Di Biologia/Merck, which is granted on 10/01/2008. [Patentcircle] [i-mak]
India: Lopinavir+Ritonavir Abbott Application Rejected
Formulation patent application which covers Lopinavir+Ritonavir combination is rejected in India. This application was opposed by i-mak, Matrix, Cipla and Osaka. Application No: 339/MUMNP/2006 (National phase of WO2005/039551) Applicant: Abbott Opponents: i-mak, Cipla, Matrix, Osaka Interesting Note: This application is related … Continue reading
Posted in Patent case
Tagged 339/MUMNP/2006, Cipla, i-mak, indian patent application, Lopinavir, Matrix, Ritonavir
Leave a comment
Roche Erlotinib Patent suit brief
Roche is an exclusive licensee for Erlitinib hydrochloride in india and patent details are below: Granted patent: IN196774 Grant Publication: 14/Sep/2007 Application: 537/DEL/1996 Applicant: Pfizer Corresponding patent: US5747498 [Orange Book listed] US expiry: 30/Mar/2015 Erlotinib was developed jointly by OSI … Continue reading